Experimental and therapeutic medicine最新文献

{"title":"Stevens-Johnson syndrome induced by fluoroquinolones in a patient with colon cancer: A case report and literature review.","authors":"Yuan Zhou, Guangye Huang, Hongxia Li","doi":"10.3892/etm.2026.13202","DOIUrl":"10.3892/etm.2026.13202","url":null,"abstract":"<p><p>Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) represent severe cutaneous adverse drug reactions characterized by extensive mucocutaneous necrosis and epidermal detachment. While these conditions are most commonly observed in association with sulfonamides and β-lactams antibiotics, emerging evidence indicates that fluoroquinolones may be linked to ~4% of cases. The current study presents a rare case of levofloxacin-induced SJS in a 55-year-old male with metastatic colon cancer. A total of 8 days after initiating levofloxacin, the patient developed a generalized erythematous rash, oral mucosal ulcerations and conjunctival hemorrhage. Despite discontinuation of the drug and the administration of dexamethasone, progressive epidermal detachment ensued, affecting 16% of the total body surface area, along with new perianal and scrotal erosions. Laboratory findings revealed persistent hypoalbuminemia, progressive azotemia and elevated procalcitonin. Despite active management, the patient ultimately succumbed to fatal septic shock and multiorgan dysfunction syndrome. This rare case highlights the need for heightened caution in administering fluoroquinolones to oncologically complex patients diagnosed with advanced colorectal cancer with malignant ascites and hypoalbuminemia prior to fluoroquinolone exposure. Furthermore, the findings suggest that malignant ascites and hypoalbuminemia may serve as novel prognostic indicators in patients with SJS/TEN and abdominal malignancies. These observations are valuable for refining current risk stratification models and provide a more precise basis for clinical decision-making in complex oncological patients to improve outcomes in this vulnerable population.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"32 2","pages":"207"},"PeriodicalIF":2.3,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13284602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148310959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening criteria for drainage-free patients after retroperitoneal laparoscopic adrenal tumor resection and their prospective validation study value.","authors":"Yan Zhao, Yu-Xuan He, Hai-Tao Li, Jing-Yi Cao, Bing Zhong, Hui Zhou","doi":"10.3892/etm.2026.13200","DOIUrl":"10.3892/etm.2026.13200","url":null,"abstract":"<p><p>Retroperitoneal laparoscopic resection is the preferred minimally invasive surgery for adrenal tumors. Patients vary greatly in postoperative drain output, but no clear criteria exist to select candidates for a drainage-free strategy. The objective of the present study was to establish clinical screening criteria for identifying patients eligible for a drainage-free strategy after retroperitoneal laparoscopic adrenal tumor resection and verify the clinical value of the criteria. A retrospective analysis was first conducted on 126 patients who underwent the aforementioned surgery. Patients were divided into two groups based on total postoperative drain output: The drainage-free group (≤60 ml, 40 cases) and the drain group (>60 ml, 86 cases). Indicators such as age and tumor diameter were compared with identify factors influencing postoperative drain output. Subsequently, a prospective validation study was carried out involving 54 patients, with 20 patients meeting the preliminary screening criteria assigned to the experimental group and 34 ineligible patients to the control group. Perioperative data and complication rates of the two groups were compared. The retrospective univariate analysis identified seven indicators (including age and tumor diameter) associated with postoperative drain output (P<0.05). Multivariate logistic regression confirmed five independent risk factors for postoperative drain output: Age [odds ratio (OR)=1.062; 95% confidence interval (CI) 1.005-1.123; P=0.033], tumor diameter (OR=2.199; 95% CI: 1.162-4.159; P=0.015), locking clip application for adrenal tissue or central vein (OR=12.081; 95% CI: 1.772-82.385; P=0.011), saponification and adhesion of adipose tissue in the surgical area (OR=0.092; 95% CI: 0.026-0.319; P<0.001) and intraoperative blood loss (OR=10.48; 95% CI: 1.025-1.072; P<0.001). In the prospective validation study, only one patient in the experimental group had postoperative drain output >60 ml (recovered with conservative treatment). The experimental group also had significantly less total drain output, shorter drain removal time and shorter hospital discharge time than the control group (P<0.05), with no significant difference in complication rates (P>0.05). In conclusion, the established screening criteria may accurately identify eligible patients. This strategy appears to safely shorten hospital stays and facilitate stratified management and may have clinical value.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"32 2","pages":"204"},"PeriodicalIF":2.3,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13266501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated network pharmacology and serum metabolomics to reveal the protective mechanism of methanolic extract of BaiYangJie on cisplatin-induced acute kidney injury in mice.","authors":"Bin Xia, Jianglong Chen, Jinhui Wang, Dalong Li, Lixia Zhang, Jing Su, Xuan Ding, Yana Lv, Shifang Liu, Xue Zhang, Tianzhen Wan, Guang Li","doi":"10.3892/etm.2026.13199","DOIUrl":"10.3892/etm.2026.13199","url":null,"abstract":"<p><p>Cisplatin, a chemotherapeutic drug, produces severe nephrotoxicity and at present, there are no effective drugs to clinically prevent or treat it. In the Dai nationality, BaiYangJie is used to treat poisoning caused by chemicals or drugs. Previous research has demonstrated that the methanolic extract of BaiYangJie (MEAG) can treat cisplatin-induced nephrotoxicity; however, its mechanism of action remains unclear. The aim of the present study was therefore to identify the potential mechanism of action of MEAG in cisplatin nephrotoxicity using a combination of network pharmacology and serum metabolomics. Initially, network pharmacology analysis was used to identify hub targets and signalling pathways involved in the renoprotective effects of MEAG. Subsequently, plasma metabolomics profiling utilising ultra performance liquid chromatography-quadrupole time-of-flight mass spectrometry technology revealed key metabolic alterations and pathway modulations associated with MEAG treatment. Finally, integrated analysis uncovered key molecular mechanisms, which were subsequently validated by western blotting and immunohistochemistry. A total of 13 endogenous metabolites were identified in serum metabolomics, primarily involved in phenylalanine metabolism and in the biosynthesis of phenylalanine, tyrosine and tryptophan. The treatment of MEAG in cis-induced acute kidney injury primarily involved regulating the inflammatory response, responses to lipid and chemical stress, the FoxO signalling pathway, arachidonic acid metabolism and the NF-κB signalling pathway. Animal experiments showed that MEAG can inhibit inflammation and the expression of the migration inhibitory factor (MIF)/NF-κB pathway. Through integrated network pharmacological analysis, metabolomic profiling and experimental validation, it was systematically elucidated that MEAG exerted its therapeutic effects through dual regulatory mechanisms: Suppressing inflammatory responses by inhibiting overactivation of the MIF/NF-κB signalling pathway and restoring phenylalanine metabolic homeostasis. These findings thus provide a mechanistic foundation for developing targeted therapeutic strategies against chemotherapy-associated nephrotoxicity.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"32 2","pages":"205"},"PeriodicalIF":2.3,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13266507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sotagliflozin ameliorates doxorubicin-induced cardiomyopathy by regulating inflammation and mitochondrial dysfunction through the AMPK/mTOR pathway.","authors":"Haifeng Liu, Danye Han, Meiling Li","doi":"10.3892/etm.2026.13201","DOIUrl":"10.3892/etm.2026.13201","url":null,"abstract":"<p><p>Sodium-glucose co-transport protein inhibitor Sotagliflozin (SOTA) has demonstrated cardiovascular benefits in diabetic patients, while doxorubicin (DOX) is widely used to generate cardiomyopathy experimental models. The present study investigated the cardioprotective mechanisms of SOTA on DOX-induced heart failure <i>in vitro</i> and <i>in vivo</i>. First, C57BL/6 mice were injected with multiple doses of DOX (total 15 mg/kg), and the <i>in vivo</i> impact of SOTA on cardiac function and cardiomyopathy-related biochemical signaling was assessed. Next, H9C2 cells were treated with DOX in the presence of SOTA to examine the changes in cell viability, mitochondrial function, inflammation, oxidative stress and cell death-related signal pathways. SOTA treatment <i>in vivo</i> alleviated cardiac dysfunction and fibrosis while reducing cardiomyocyte apoptosis, inflammation, oxidative stress and mitochondrial dysfunction. <i>In vitro</i>, H9c2 cells exposed to DOX in the presence of SOTA exhibited enhanced cell viability and mitigated apoptosis, inflammation, oxidative stress and mitochondrial damage. Furthermore, cleaved caspase-3 and inflammatory cytokine (IL-6, IL-1β and TNF-α) levels were decreased. Reactive oxygen species and mitochondrial Ca²⁺ loading were reduced. Mitochondrial dysfunction was also improved, as indicated by increased JC-1 aggregates and Bcl-2/Bax ratios. Notably, SOTA activated 5' AMP-activated protein kinase (AMPK) and inhibited mTOR signaling while protecting from DOX-induced cardiomyopathy, suggesting SOTA as a promising therapeutic for heart failure treatment.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"32 2","pages":"206"},"PeriodicalIF":2.3,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13266505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>LMNA</i> c.1622G>A mutation and myopathic changes in a family with limb-girdle muscular dystrophy: A case report.","authors":"Yanling Zhu, Qiushi Wang, Tiefeng Zhang","doi":"10.3892/etm.2026.13198","DOIUrl":"10.3892/etm.2026.13198","url":null,"abstract":"<p><p>The present study reports a case of limb-girdle muscular dystrophy (LGMD) associated with a pathogenic lamin A/C (<i>LMNA</i>) mutation (c.1622G>A). Notably, this case expands the phenotypic and genotypic spectrum of LMNA-related LGMD, and provides novel familial clinical and genetic evidence for this rare mutation. Genetic sequencing revealed a heterozygous mutation in both the proband and the mother of the proband, suggesting autosomal dominant inheritance. Electromyography (EMG) revealed reduced nerve conduction velocity and abnormal potentials in the proband and mother, indicating muscle weakness and atrophy. Magnetic resonance imaging (MRI) results showed symmetric muscle atrophy in the proximal muscles of the lower legs, with fatty tissue replacement. Both the proband and mother had elevated creatine kinase levels, whereas the father had normal levels. Transthoracic echocardiography ruled out severe heart disorders in the proband and mother. In conclusion, EMG and MRI findings indicated myopathic changes in the proband and the mother of the proband, confirming the significance of this mutation in LGMD. This familial case adds novel clinical, electrophysiological and imaging data to the existing literature on LMNA-associated LGMD. Further genetic and clinical evaluations are required to understand the long-term prognosis and potential treatment strategies for LMNA-related LGMD.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"32 2","pages":"202"},"PeriodicalIF":2.3,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13266504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete ureteral duplication with occult calculi: A case report.","authors":"Haiyan Zheng, Li Wang, Rui Yang, Shenghao Niu, Faying Yang, Jiaxi Yao","doi":"10.3892/etm.2026.13194","DOIUrl":"10.3892/etm.2026.13194","url":null,"abstract":"<p><p>Duplication of the kidney and ureter is a relatively rare congenital malformation compared with other systemic malformations. It is even rarer for the duplicate to have stones inside; therefore, the present study reports the case of a patient with complete repetitive ureteral malformations combined with occult stones who showed marked improvement in symptoms and good recovery after surgical treatment. The patient received a timely diagnosis and achieved a good treatment outcome. The patient was satisfied with the treatment and had a good follow-up. Early and accurate diagnosis and timely treatment are crucial for patients with recurrent ureteral malformations combined with occult stones, and can effectively improve patient prognosis.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"32 2","pages":"199"},"PeriodicalIF":2.3,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13267074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor Treating Fields modulate apoptotic and immune programs in T-cell acute lymphoblastic leukemia cell lines.","authors":"Jinju Heo, Myonggeun Yoon","doi":"10.3892/etm.2026.13195","DOIUrl":"10.3892/etm.2026.13195","url":null,"abstract":"<p><p>T-cell acute lymphoblastic leukemia (T-ALL) is a highly aggressive hematologic malignancy with limited treatment options for relapsed or refractory disease. Tumor Treating Fields (TTFields), low-intensity alternating electric fields that disrupt mitotic spindle assembly, have been clinically determined in numerous solid tumors, yet their effects in hematologic malignancies remain incompletely understood. In the present study, the cellular responses of T-ALL cells to TTFields were examined. Jurkat and MOLT-4 cells were exposed to 150 kHz and 0.7 V/cm fields for up to 96 h. TTFields treatment progressively suppressed cell proliferation, induced G₂/M-phase arrest, altered cell-cycle distribution, increased apoptotic fractions and increased late-apoptotic fractions. TTFields exposure also increased side-scatter intensity (indicative of increased cellular granularity or internal complexity) and MitoTracker green fluorescence in both cell lines. Intracellular ATP levels were reduced in Jurkat cells, whereas no significant change was observed in MOLT-4 cells. In parallel, transcriptional analyses revealed downregulation of CD69 and IL-2 and upregulation of RELA proto-oncogene, NF-κB subunit and CBL proto-oncogene B. Collectively, these results demonstrate that TTFields induces cytostatic and apoptotic effects accompanied by measurable structural, bioenergetic and transcriptional alterations in T-ALL cells, supporting further investigation of TTFields as a physical therapeutic approach for hematologic malignancies.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"32 2","pages":"200"},"PeriodicalIF":2.3,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13267092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing management of immune checkpoint inhibitor-induced inflammatory arthritis: A case series and literature review.","authors":"Yuanyuan Wang, Yingmei Wen, Jinxiong Xia, Hongyan Feng, Fei Wu, Dafu Ye, Yanjun Gao, Qingqing Li, Yi Yao","doi":"10.3892/etm.2026.13196","DOIUrl":"10.3892/etm.2026.13196","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) are widely applied in the treatment of various malignant tumors, leading to notable improvements in patient prognosis. However, with their increased use, various immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-IA), may develop, affecting clinical evaluation and treatment decisions. The present report presents 3 cases of ICI-IA and reviews the literature on its clinical features, diagnosis and therapeutic approaches. The first patient, who had been diagnosed with metastatic bladder cancer, developed limb joint pain after undergoing combination therapy involving ICIs and chemotherapy. Laboratory tests showed elevated levels of C-reactive protein and interleukin (IL)-6. Bone scintigraphy excluded bone metastasis, and the symptoms of the patient improved following corticosteroid therapy. The second patient had advanced cervical cancer and a history of rheumatoid arthritis. Following multiple cycles of ICI combined with anti-angiogenic treatment, the patient experienced recurrent joint swelling and pain, accompanied by elevated IL-6 and IL-10 levels. Bone scintigraphy excluded bone metastasis, and the symptoms were controlled with corticosteroid therapy. The third patient had advanced lung cancer and developed persistent pain in the shoulders, knees and ankles during immunotherapy. Corticosteroid therapy effectively controlled the symptoms after bone metastases and autoimmune diseases were excluded. These cases illustrate that ICI-IA is a clinically relevant irAE. Early recognition and management are crucial for improving patient prognosis. A thorough understanding of the pathogenesis of ICI-IA is essential for optimizing treatment strategies and improving quality of life.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"32 2","pages":"201"},"PeriodicalIF":2.3,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13267082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148267528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amplification of heterogeneous nuclear ribonucleoprotein A/B aids in immune infiltration regulation and breast cancer tumorigenesis.","authors":"Jiachao Xu, Qian Han, Libin Chen, Min Yang, Jun Huang, Shanhong Lin, Shengmin Zhang","doi":"10.3892/etm.2026.13193","DOIUrl":"10.3892/etm.2026.13193","url":null,"abstract":"<p><p>Breast carcinoma ranks among the most prevalent malignant tumors affecting women worldwide. The discovery of biomarkers is important in the diagnosis of breast cancer and the prediction of clinical outcomes in afflicted patients. Heterogeneous nuclear ribonucleoprotein (HNRNP)-AB belongs to the extensive HNRNP superfamily; however, its exact role in the progression of breast carcinoma has not yet been fully clarified. The present study drew upon breast cancer sample datasets retrieved from The Cancer Genome Atlas and Human Protein Atlas databases to examine the expression patterns and prognosis-associated data of HNRNPAB in clinical specimens. Reverse transcription-quantitative PCR was employed to validate the efficiency of HNRNPAB knockdown in breast cancer cell lines. Transwell assays and Cell Counting Kit-8 tests further demonstrated alterations in migratory, invasive and proliferative capacities following small interfering RNA-mediated HNRNPAB knockdown. Bioinformatics was utilized to investigate numerous aspects of HNRNPAB in cancerous tissues, including its mRNA expression profile, prognostic value, signaling pathway remodeling, interaction with cancer stem cells and regulatory effects on the tumor immune microenvironment, as well as immunotherapeutic responses. Compared with normal breast tissues, HNRNPAB exhibited elevated expression in breast cancer tissues, upregulation that appeared to be associated with overall survival outcomes, sex characteristics, lymph node metastasis staging and adverse prognostic profiles in patients. Functionally, HNRNPAB depletion was found to suppress the proliferative activity, migratory potential and invasive capabilities of breast cancer cells. Mechanistically, bioinformatics analyses indicated that high HNRNPAB expression was associated with the tumor immune infiltration status in affected individuals. In summary, the present study determined that HNRNPAB exerted a key regulatory effect on the development and progression of breast cancer and therefore its upregulation holds promise as a diagnostic and prognostic marker. In addition, HNRNPAB serves a notable role in cancer immunotherapy, supporting its potential as a novel therapeutic candidate for the early detection and prognostic evaluation of breast cancer.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"32 1","pages":"198"},"PeriodicalIF":2.3,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13237579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148201791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-analysis of the efficacy of reverse total shoulder arthroplasty and open reduction and internal fixation in the treatment of proximal humerus fractures.","authors":"Yuan Li, Meng-Xuan Niu, Fang-Zheng He, Xin Qin, Wei-Wei Wang, Peng-Fei Han","doi":"10.3892/etm.2026.13191","DOIUrl":"10.3892/etm.2026.13191","url":null,"abstract":"<p><p>A proximal humerus fracture (PHF) is a common type of fracture that mostly occurs in middle-aged and elderly individuals and is often caused by indirect trauma. Severe pain typically occurs at the fracture site, accompanied by soft tissue swelling around the injured area, a limited range of motion in the shoulder joint, and visible shoulder deformity. Surgical intervention is a common treatment approach. Reverse total shoulder arthroplasty (RTSA) and open reduction and internal fixation (ORIF) are commonly used surgical methods; however, their effects on patients vary. The present meta-analysis compares their intraoperative and postoperative outcomes to assist surgeons in making informed decisions and improving patient treatment outcomes. The aim of the present study was to compare the intraoperative and postoperative outcomes of RTSA and ORIF in the treatment of PHFs. Literature on the treatment of PHFs by RTSA and ORIF published in databases, such as Pubmed, Embase, Cinahl, Cochrane Library, CNKI and Wanfang was retrieved. A total of 232 relevant articles were retrieved, and finally, 7 studies were included. The quality of the studies was evaluated according to the Cochrane systematic review methodology. After extracting the data, meta-analysis was performed using Review Manager 5.4 software. In the treatment of PHF, the postoperative forward flexion and abduction angles and the operation duration of ORIF were lower than those of RTSA, and the differences were statistically significant [95% confidence interval (CI) (18.64, 36.94), P<0.00001; 95% CI (0.20, 30.15), P=0.05; [95% CI (13.44, 37.65), P<0.0001]. In addition, there were no statistically significant differences between the two groups in terms of external rotation angle, DASH score, Constant score, and other outcome measures. In conclusion, in the treatment of PHF, RTSA offers improved postoperative forward flexion and abduction angles, while ORIF has the advantage of shorter operation duration. Therefore, the choice between the two surgical approaches should be based on the individual patient's condition.</p>","PeriodicalId":94002,"journal":{"name":"Experimental and therapeutic medicine","volume":"32 1","pages":"196"},"PeriodicalIF":2.3,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13237578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148201789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}